Product Images Yescarta

The text is a record of a patient, identified by their Kite Patient ID, receiving a therapeutic infusion of a drug called axicabtagene ciloleucel, which has the brand name YESCARTA. The lot number of the drug is also specified along with the ID of the hospital patient. The details of the patient's name and date of birth are given as well as their ID prior to the expiration date. The remaining parts of the text seem to be illegible or unrelated.*

This is a description of a medication called Axicabtagene Ciloleucel developed by Kite Pharma, Inc. There is also information about a cellular order, a lot number, and a site called FXX. Additionally, there is an address and a phone number listed.*

Axicabtagene ciloleucel (YESCARTA) is a treatment for autologous and intravenous use only, containing a maximum of 2 x 10¢ autologous anti-CD19 CAR T cells in approximately 68 mL suspension containing 5% DMSO USP. The contents of the sterile bag need to be gently mixed while thawing and should not be irradiated. There is no U.S. standard of potency for the medication, and it has not been evaluated for infectious substances. The medication is manufactured with gentamicin, preservative-free and must be shipped and stored in vapor phase of liquid nitrogen < -150°C substances. Full prescribing information and administration instructions can be found in the package insert. The manufacturer of Axicabtagene ciloleucel is Kite Pharma, Inc., located in Santa Monica, CA.*

Axicabtagene ciloleucel is a potent anti-CD19 CAR T cell therapy used for infusion. It comes in a sterile bag and each bag contains approximately 2 x 10^8 autologous anti-CD19 CAR T cells in a 68 mL suspension with 5% DMSO USP. It is manufactured by Kite Pharma, Inc. and should be shipped and stored in vapor phase liquid nitrogen < -150°C. It is preservative free, but manufactured with gentamicin, and has not been evaluated for infectious substances. See the package insert for full instructions on administration.*

This appears to be a chart or graph showing the results of a clinical trial comparing the effectiveness of a treatment called YESCARTA versus a standard therapy. The x-axis is labeled with time since randomization in months, and the y-axis is unlabeled but appears to represent percentage or number of subjects. The chart shows that at the beginning of the trial, 100 subjects were enrolled in both the YESCARTA and Standard Therapy arms. As time goes on, the number of subjects at risk decreases in both arms, with more subjects dropping out of the Standard Therapy arm. At the last time point shown (27 months), there are 2 subjects at risk in the YESCARTA arm and 6 in the Standard Therapy arm. The chart also shows that the YESCARTA arm appears to have a higher survival rate over time than the Standard Therapy arm, based on the difference in the number/percentage of subjects at risk between the two arms at each time point.*